top of page

Post-ESMO update & “What now for CDK4/6 inhibitors?”
8th November 2022 | 18:30 – 20:00 GMT
This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Ltd.
UK | November 2022 | 248254
Your attendance at the event is governed by our Healthcare Professional Event Attendance Terms. By attending the event, you are agreeing to be bound by such terms.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK).
Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about a product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com
bottom of page